Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Projected time to elimination of cervical cancer in the USA: a comparative modelling study.

Burger EA, Smith MA, Killen J, Sy S, Simms KT, Canfell K, Kim JJ.

Lancet Public Health. 2020 Feb 10. pii: S2468-2667(20)30006-2. doi: 10.1016/S2468-2667(20)30006-2. [Epub ahead of print]

2.

Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.

Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, Burger EA, Martin D, Nguyen DTN, Bénard É, Sy S, Regan C, Drolet M, Gingras G, Laprise JF, Torode J, Smith MA, Fidarova E, Trapani D, Bray F, Ilbawi A, Broutet N, Hutubessy R.

Lancet. 2020 Feb 22;395(10224):591-603. doi: 10.1016/S0140-6736(20)30157-4. Epub 2020 Jan 30.

3.

Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.

Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, Martin D, Simms KT, Bénard É, Boily MC, Sy S, Regan C, Keane A, Caruana M, Nguyen DTN, Smith MA, Laprise JF, Jit M, Alary M, Bray F, Fidarova E, Elsheikh F, Bloem PJN, Broutet N, Hutubessy R.

Lancet. 2020 Feb 22;395(10224):575-590. doi: 10.1016/S0140-6736(20)30068-4. Epub 2020 Jan 30.

4.

Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis.

Burger EA, de Kok IMCM, Groene E, Killen J, Canfell K, Kulasingam S, Kuntz KM, Matthijsse S, Regan C, Simms K, Smith M, Sy S, Alarid-Escudero F, Vaidyanathan V, van Ballegooijen M, Kim JJ.

J Natl Cancer Inst. 2019 Dec 10. pii: djz227. doi: 10.1093/jnci/djz227. [Epub ahead of print]

PMID:
31821501
5.

Impact and Cost-Effectiveness of Human Papillomavirus Vaccination Campaigns.

Portnoy A, Campos NG, Sy S, Burger EA, Cohen J, Regan C, Kim JJ.

Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):22-30. doi: 10.1158/1055-9965.EPI-19-0767. Epub 2019 Oct 30.

PMID:
31666282
6.

Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact.

Rodin D, Burger EA, Atun R, Barton M, Gospodarowicz M, Grover S, Hanna TP, Jaffray DA, Knaul FM, Lievens Y, Zubizarreta E, Milosevic M.

Lancet Oncol. 2019 Jul;20(7):915-923. doi: 10.1016/S1470-2045(19)30308-0. Epub 2019 May 28.

7.

The healthcare costs of treating human papillomavirus-related cancers in Norway.

Hylin H, Thrane H, Pedersen K, Kristiansen IS, Burger EA.

BMC Cancer. 2019 May 7;19(1):426. doi: 10.1186/s12885-019-5596-2.

8.

Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.

Castle PE, Xie X, Xue X, Poitras NE, Lorey TS, Kinney WK, Wentzensen N, Strickler HD, Burger EA, Schiffman M.

Prev Med. 2019 Jan;118:44-50. doi: 10.1016/j.ypmed.2018.10.001. Epub 2018 Oct 11.

PMID:
30316878
9.

Screening for Cervical Cancer in Primary Care: A Decision Analysis for the U.S. Preventive Services Task Force [Internet].

Kim JJ, Burger EA, Regan C, Sy S.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Aug. No abstract available.

PMID:
30212064
Free Books & Documents
10.

Screening for Cervical Cancer in Primary Care: A Decision Analysis for the US Preventive Services Task Force.

Kim JJ, Burger EA, Regan C, Sy S.

JAMA. 2018 Aug 21;320(7):706-714. doi: 10.1001/jama.2017.19872.

PMID:
30140882
11.

Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.

Burger EA, Campos NG, Sy S, Regan C, Kim JJ.

Vaccine. 2018 Aug 6;36(32 Pt A):4823-4829. doi: 10.1016/j.vaccine.2018.04.061. Epub 2018 May 26.

12.

Development and Calibration of a Mathematical Model of Anal Carcinogenesis for High-Risk HIV-Infected Men.

Burger EA, Dyer MA, Sy S, Palefsky JM, de Pokomandy A, Coutlee F, Silverberg MJ, Kim JJ.

J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):10-19. doi: 10.1097/QAI.0000000000001727.

13.

Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S.

Castle PE, Wheeler CM, Campos NG, Sy S, Burger EA, Kim JJ; New Mexico HPV Pap Registry Steering Committee.

Prev Med. 2018 Jun;111:177-179. doi: 10.1016/j.ypmed.2018.03.011. Epub 2018 Mar 14.

14.

An overview of cervical cancer epidemiology and prevention in Scandinavia.

Pedersen K, Fogelberg S, Thamsborg LH, Clements M, Nygård M, Kristiansen IS, Lynge E, Sparén P, Kim JJ, Burger EA.

Acta Obstet Gynecol Scand. 2018 Jul;97(7):795-807. doi: 10.1111/aogs.13313. Epub 2018 Feb 23. Review.

PMID:
29388202
15.

Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.

Pedersen K, Burger EA, Nygård M, Kristiansen IS, Kim JJ.

Eur J Cancer. 2018 Mar;91:68-75. doi: 10.1016/j.ejca.2017.12.018. Epub 2018 Jan 12.

16.

Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.

Brisson M, Bénard É, Drolet M, Bogaards JA, Baussano I, Vänskä S, Jit M, Boily MC, Smith MA, Berkhof J, Canfell K, Chesson HW, Burger EA, Choi YH, De Blasio BF, De Vlas SJ, Guzzetta G, Hontelez JAC, Horn J, Jepsen MR, Kim JJ, Lazzarato F, Matthijsse SM, Mikolajczyk R, Pavelyev A, Pillsbury M, Shafer LA, Tully SP, Turner HC, Usher C, Walsh C.

Lancet Public Health. 2016 Nov;1(1):e8-e17. doi: 10.1016/S2468-2667(16)30001-9. Epub 2016 Sep 27. Review.

17.

Advancing the evaluation of cervical cancer screening: development and application of a longitudinal adherence metric.

Pedersen K, Burger EA, Campbell S, Nygård M, Aas E, Lönnberg S.

Eur J Public Health. 2017 Dec 1;27(6):1089-1094. doi: 10.1093/eurpub/ckx073.

PMID:
29186461
18.

Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study.

Rutter CM, Kim JJ, Meester RGS, Sprague BL, Burger EA, Zauber AG, Ergun MA, Campos NG, Doubeni CA, Trentham-Dietz A, Sy S, Alagoz O, Stout N, Lansdorp-Vogelaar I, Corley DA, Tosteson ANA.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):158-164. doi: 10.1158/1055-9965.EPI-17-0378. Epub 2017 Nov 17.

19.

Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway.

Burger EA, Pedersen K, Sy S, Kristiansen IS, Kim JJ.

Br J Cancer. 2017 Sep 5;117(6):783-790. doi: 10.1038/bjc.2017.248. Epub 2017 Aug 3.

20.
21.

Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing.

Pedersen K, Burger EA, Sy S, Kristiansen IS, Kim JJ.

Gynecol Oncol. 2016 Nov;143(2):326-333. doi: 10.1016/j.ygyno.2016.08.231. Epub 2016 Aug 17.

22.

Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.

Kim JJ, Burger EA, Sy S, Campos NG.

J Natl Cancer Inst. 2016 Oct 18;109(2). pii: djw216. Print 2017 Feb.

23.

The Cost-Effectiveness of Cervical Self-Sampling to Improve Routine Cervical Cancer Screening: The Importance of Respondent Screening History and Compliance.

Burger EA, Sy S, Nygård M, Kim JJ.

Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):95-103. doi: 10.1158/1055-9965.EPI-16-0350. Epub 2016 Sep 13.

24.

Age of human papillomavirus vaccination?

Castle PE, Burger EA.

Lancet Infect Dis. 2016 Oct;16(10):1091-1093. doi: 10.1016/S1473-3099(16)30144-X. Epub 2016 Jun 28. No abstract available.

PMID:
27373899
25.

Using novel biomarkers to triage young adult women with minor cervical lesions: a cost-effectiveness analysis.

Pedersen K, Sørbye SW, Kristiansen IS, Burger EA.

BJOG. 2017 Feb;124(3):474-484. doi: 10.1111/1471-0528.14135. Epub 2016 Jun 6.

26.

Racial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines.

Burger EA, Lee K, Saraiya M, Thompson TD, Chesson HW, Markowitz LE, Kim JJ.

Cancer. 2016 Jul 1;122(13):2057-66. doi: 10.1002/cncr.30007. Epub 2016 Apr 28.

27.

Using Decision-Analytic Modeling to Isolate Interventions That Are Feasible, Efficient and Optimal: An Application from the Norwegian Cervical Cancer Screening Program.

Pedersen K, Sørbye SW, Burger EA, Lönnberg S, Kristiansen IS.

Value Health. 2015 Dec;18(8):1088-97. doi: 10.1016/j.jval.2015.08.003. Epub 2015 Sep 16.

28.

Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.

Kim JJ, Campos NG, Sy S, Burger EA, Cuzick J, Castle PE, Hunt WC, Waxman A, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Ann Intern Med. 2015 Oct 20;163(8):589-97. doi: 10.7326/M15-0420. Epub 2015 Sep 29.

29.

Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example.

Rochau U, Jahn B, Qerimi V, Burger EA, Kurzthaler C, Kluibenschaedl M, Willenbacher E, Gastl G, Willenbacher W, Siebert U.

Crit Rev Oncol Hematol. 2015 May;94(2):164-78. doi: 10.1016/j.critrevonc.2014.12.017. Epub 2014 Dec 31. Review.

PMID:
25620327
30.

Systematic Overview On Value-Of Information Analyses In Cancer Research.

Rochau U, Schnell-Inderst P, Burger EA, Baldauf M, Kühne F, Jahn B, Siebert U.

Value Health. 2014 Nov;17(7):A559. doi: 10.1016/j.jval.2014.08.1846. Epub 2014 Oct 26. No abstract available.

31.

An updated natural history model of cervical cancer: derivation of model parameters.

Campos NG, Burger EA, Sy S, Sharma M, Schiffman M, Rodriguez AC, Hildesheim A, Herrero R, Kim JJ.

Am J Epidemiol. 2014 Sep 1;180(5):545-55. doi: 10.1093/aje/kwu159. Epub 2014 Jul 31.

32.

Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway.

Burger EA, Sy S, Nygård M, Kristiansen IS, Kim JJ.

J Infect Dis. 2015 Jan 15;211(2):206-15. doi: 10.1093/infdis/jiu413. Epub 2014 Jul 23.

33.

Does the primary screening test influence women's anxiety and intention to screen for cervical cancer? A randomized survey of Norwegian women.

Burger EA, Nygård M, Gyrd-Hansen D, Moger TA, Kristiansen IS.

BMC Public Health. 2014 Apr 15;14:360. doi: 10.1186/1471-2458-14-360.

34.

Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys.

Burger EA, Sy S, Nygård M, Kristiansen IS, Kim JJ.

PLoS One. 2014 Mar 20;9(3):e89974. doi: 10.1371/journal.pone.0089974. eCollection 2014.

35.

The value of improving failures within a cervical cancer screening program: an example from Norway.

Burger EA, Kim JJ.

Int J Cancer. 2014 Oct 15;135(8):1931-9. doi: 10.1002/ijc.28838. Epub 2014 Mar 20.

36.

Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway.

Burger EA, Ortendahl JD, Sy S, Kristiansen IS, Kim JJ.

Br J Cancer. 2012 Apr 24;106(9):1571-8. doi: 10.1038/bjc.2012.94. Epub 2012 Mar 22.

37.
38.

HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review.

Burger EA, Kornør H, Klemp M, Lauvrak V, Kristiansen IS.

Gynecol Oncol. 2011 Mar;120(3):430-8. doi: 10.1016/j.ygyno.2010.11.013. Epub 2010 Dec 4. Review.

PMID:
21130490

Supplemental Content

Loading ...
Support Center